Nefiracetam
Investigational pyrrolidone derivative also known as DM-9384. Human pharmacokinetics are linear and moderately short, but clinical development did not establish an approved indication. A post-stroke depression/apathy trial reported a dose-related apathy signal in a subgroup, while most mechanistic and cognitive evidence remains preclinical.
Projected serum levels — 100 mg, once daily
Maintenance schedule: 100 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 61.9 mg, trough ≈ 1.4 mg body load. Population-based estimate over 15 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Investigational Nootropic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 4 h
- Common dose
- 100 mg
- Suggested maximum
- 300 mg/day
- Reference dose range
- 25–300 mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers
Healthy Japanese men received single 10-200 mg oral doses and 200 mg three times daily for seven days. Cmax occurred within two hours, terminal half-life was 3-5 hours, and Cmax and AUC increased linearly with dose.
-
Double-blind treatment of apathy in patients with poststroke depression using nefiracetam
Among 137 randomized stroke patients with major depression, 70 met apathy criteria and received placebo, 600 mg/day, or 900 mg/day. Apathy scores improved more in the 900 mg subgroup, but this secondary subgroup result…
-
Effects of nefiracetam on amnesia animal models with neuronal dysfunctions
Review of animal amnesia models described behavioral and neurochemical effects across experimentally induced impairments. These findings are preclinical and cannot demonstrate cognitive enhancement or safety in healthy…
3 published studies referenced in the app, each with a plain-language summary.